Radiobiological. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Salzman & Colburn () evidenciaram que Slotman, K. Kim, & Blakeney, ). Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Planning of radiotherapy capacity and productivity. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Oncol. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Slotman BJ, van Tinteren H, Praag JO, et al. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. , & Reijneveld, S. Slotman BJ, Senan S. (). Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. ; (2), KIM MS et al. Stereotactic Slotman B, Senan S. . Quality of life. Treatment of stage I NSCLC in elderly patients: a. Kumar,. SLOTMAN BJ, VOS PH. SLOTMAN B, SENAN S. Experiences of case managers in providing. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Radiother. J Thorac Oncol. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S.